Apimeds Pharmaceuticals US, Inc. (APUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has a cash flow conversion efficiency ratio of -0.017x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($126.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see APUS market cap for the company's overall valuation and market capitalisation.
Apimeds Pharmaceuticals US, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apimeds Pharmaceuticals US, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their cash flow conversion efficiency. See Apimeds Pharmaceuticals US, Inc. (APUS) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ostrom Climate Solutions Inc
V:COO
|
-0.097x |
|
PolyPlank publ AB
ST:POLY
|
0.323x |
|
Serabi Gold PLC
LSE:SRB
|
0.137x |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
-0.028x |
|
Scout Security Ltd
AU:SCT
|
-0.203x |
|
John Wood Group PLC
LSE:WG
|
-0.763x |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
-0.044x |
|
CL8 Holdings Ltd
AU:CL8
|
0.158x |
Annual Cash Flow Conversion Efficiency for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. View Apimeds Pharmaceuticals US, Inc. (APUS) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $153.35 Million | $-8.93 Million | -0.058x | -110.78% |
| 2024-12-31 | $-1.36 Million | $-733.53K | 0.540x | +102.74% |
| 2023-12-31 | $31.87K | $-627.79K | -19.698x | -3236.44% |
| 2022-12-31 | $-713.61K | $-448.17K | 0.628x | -81.80% |
| 2021-12-31 | $-238.48K | $-823.11K | 3.451x | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.